| Literature DB >> 31033087 |
Alice Fiévet1,2,3, Dorine Bellanger1,2, Stéphanie Valence4,5,6,7, Lenha Mobuchon1,2, Alexandra Afenjar8, Fabienne Giuliano9, Catherine Dubois d'Enghien3, Béatrice Parfait10, Jean-Michel Pedespan11, Nathalie Auger12, Guillaume Rieunier1,2, Agnès Collet3, Lydie Burglen5,6,7,13, Dominique Stoppa-Lyonnet2,3,14, Marc-Henri Stern1,2,3.
Abstract
Ataxia-telangiectasia-like disorder (ATLD) is a rare genomic instability syndrome caused by biallelic variants of MRE11 (meiotic recombination 11) characterized by progressive cerebellar ataxia and typical karyotype abnormalities. These symptoms are common to those of ataxia-telangiectasia, which is consistent with the key role of MRE11 in ataxia-telangiectasia mutated (ATM) activation after DNA double-strand breaks. Three unrelated French patients were referred with ataxia. Only one had typical karyotype abnormalities. Unreported biallelic MRE11 variants were found in these three cases. Interestingly, one variant (c.424G>A) was present in two cases and haplotype analysis strongly suggested a French founder variant. Variants c.544G>A and c.314+4_314+7del lead to splice defects. The level of MRE11 in lymphoblastoid cell lines was consistently and dramatically reduced. Functional consequences were evaluated on activation of the ATM pathway via phosphorylation of ATM targets (KAP1 and CHK2), but no consistent defect was observed. However, an S-phase checkpoint activation defect after camptothecin was observed in these patients with ATLD. In conclusion, we report the first three French ATLD patients and a French founder variant, and propose an S-phase checkpoint activation study to evaluate the pathogenicity of MRE11 variants.Entities:
Keywords: MRN; ataxia; ataxia-telangiectasia mutated (ATM); ataxia-telangiectasia-like disorder (ATLD); checkpoint; meiotic recombination 11 (MRE11)
Mesh:
Substances:
Year: 2019 PMID: 31033087 DOI: 10.1002/humu.23773
Source DB: PubMed Journal: Hum Mutat ISSN: 1059-7794 Impact factor: 4.878